With 809 citations, a clinical trial by Barcelona’s August Pi i Sunyer Biomedical Research Institute (IDIBAPS) is the world’s most often cited study in the field of cancer. The study, published in 2008 in the New England Journal of Medicine, demonstrates the positive effect of the drug Sorafenib on the survival of patients with advanced liver cancer